Literature DB >> 6814336

A standardised multicentre procedure for plasma gonadotrophin radioimmunoassay.

K M Ferguson, M Hayes, S L Jeffcoate.   

Abstract

A radioimmunoassay method for the assay of luteinising hormone (LH) and follicle-stimulating hormone (FSH) in serum/plasma has been designed for use in laboratories of varying expertise in the United Kingdom. The major sources of experimental error leading to poor within-laboratory performance and between-laboratory comparability were identified: quality of tracer, use of calibration standards, and separation procedure. A simple rugged kit was designed which was extensively tested first in our laboratory and then in a small multi-centre field trial before being made available. It is now used routinely by 26 health service and research laboratories. The working range of the assays is 1-50 IU/l (LH) and 0.3-16 IU/l (FSH). The between-batch reproducibility was 5-11% (CV) over the dose range 4.8-18 IU/l (LH) and 1.6-15 IU/l (FSH).

Mesh:

Substances:

Year:  1982        PMID: 6814336     DOI: 10.1177/000456328201900507

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  13 in total

1.  Studies of gonadotrophin pulsatility and pelvic ultrasound examinations distinguish between isolated premature thelarche and central precocious puberty.

Authors:  R Stanhope; N A Abdulwahid; J Adams; C G Brook
Journal:  Eur J Pediatr       Date:  1986-08       Impact factor: 3.183

2.  Comparison of the pharmacokinetics and pharmacodynamics of unformulated and formulated 4-hydroxyandrostenedione taken orally by healthy men.

Authors:  M Dowsett; P Lloyd
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Isolated adrenocorticotropin deficiency presenting as primary infertility.

Authors:  S L Atkin; E A Masson; M C White
Journal:  J Endocrinol Invest       Date:  1995-06       Impact factor: 4.256

4.  Normal postnatal androgen production and action in isolated micropenis and isolated hypospadias.

Authors:  B A Evans; D M Williams; I A Hughes
Journal:  Arch Dis Child       Date:  1991-09       Impact factor: 3.791

5.  Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.

Authors:  M Dowsett; A L Harris; I E Smith; S L Jeffcoate
Journal:  Br J Cancer       Date:  1984-09       Impact factor: 7.640

6.  Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer: clinical and endocrine effects.

Authors:  I L Crighton; M Dowsett; A Lal; A Man; I E Smith
Journal:  Br J Cancer       Date:  1989-10       Impact factor: 7.640

7.  The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.

Authors:  R C Stein; M Dowsett; A Hedley; J C Gazet; H T Ford; R C Coombes
Journal:  Br J Cancer       Date:  1990-10       Impact factor: 7.640

8.  Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone.

Authors:  P A Philip; J Carmichael; K Tonkin; P K Buamah; J Britton; M Dowsett; A L Harris
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

9.  Phase II clinical and endocrine study of Anandron (RU-23908) in advanced post-menopausal breast cancer.

Authors:  M J Millward; B M Cantwell; M Dowsett; J Carmichael; A L Harris
Journal:  Br J Cancer       Date:  1991-05       Impact factor: 7.640

10.  Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study.

Authors:  R C Stein; M Dowsett; D C Cunningham; J Davenport; H T Ford; J C Gazet; E von Angerer; R C Coombes
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.